Sartorius Stedim Biotech Holds Annual Shareholders' Meeting

The Combined Annual Shareholders' Meeting of Sartorius Stedim Biotech S.A. took place on March 24, 2026, in Aubagne, France. The shareholders discharged all directors by a large majority, reinforcing confidence in the leadership team. The current Board comprises Michael Grosse as Chairman and René Fáber as CEO, among others, including a Director Representing Employees and a Lead Independent Director.

All proposed resolutions were approved, including a dividend of 0.69 euros per share for fiscal 2025, translating to a total payout of 67.1 million euros. The dividend will be distributed starting April 2, 2026. The company, listed on Euronext Paris, remains a significant player in the biopharmaceutical industry, with substantial operations worldwide.